An estimated half a million cancers were prevented by colorectal cancer screening in the United States from 1976 to 2009, report researchers from the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale Cancer Center. Their study appears in the journal Cancer.
During this more than 30-year time span, as increasing numbers of men and women underwent cancer screening tests – including fecal occult blood testing, sigmoidoscopies, and colonoscopies – colorectal cancer rates declined significantly, the researchers found.
The Yale COPPER team studied the colorectal cancer incidence data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results database, along with its Cancer Trends Progress Report. Researchers found that the incidence of late-stage cancer decreased from 118 cases per 100,000 people over the age of 50, to 74 cases per 100,000. They also found that the incidence of early-stage cancers declined from 77 to 67 cases per 100,000 people over the age of 50, during a period where cancer screening increased from 34.8% to 66.1%. After adjusting for trends in cancer incidence, the authors calculated that there was a reduction of 550,000 cancers during this period of increasing screening.
“These numbers represent real patients and families who have been spared the trauma of a cancer diagnosis and treatment,” said the study’s senior author, James Yu, M.D., assistant professor of therapeutic radiology at Yale School of Medicine. “Colorectal cancer screening is one of the major successes in cancer care.”
These findings are particularly significant in light of recent controversy surrounding mammography screening for breast cancer, and suggestions that it may result in false positive diagnoses and overtreatment, note the researchers. “The efficacy of colorectal cancer screening is important to highlight, especially at a time when there has been a national discussion about screening for other types of cancer,” said Cary Gross, M.D., a co-author on the study and director of the Yale COPPER Center.
Other authors are Daniel Yang, Cary Gross, M.D., and Pamela Soulos of Yale School of Medicine and the Cancer Outcomes, Public Policy, and Effectiveness Research Center at Yale.
Gross received funding from Medtronic Inc. and Johnson & Johnson as a collaborator on the Yale University Open Data Access Project, which is facilitating the sharing and objective analysis of clinical trial data. Yu is supported by Clinical and Translational Science Award KL2 TR000140 from the National Center for Advancing Translational Science, a component of the National Institutes of Health (NIH), and by the NIH Roadmap for Medical Research. Disclosure: Gross and Yu report funding from 21st-Century Oncology LLC.